Skip to content

Study · Randomized controlled trial · 2022

3 results

Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.

van Ruiten CC, Veltman DJ, Schrantee A, van Bloemendaal L, Barkhof F, Kramer MHH, Nieuwdorp M, IJzerman RG

The Journal of clinical endocrinology and metabolism1 May 2022Cited by 23 (Europe PMC)

PMID35134184 (opens in a new tab)PMCIDPMC9113812 (opens in a new tab)DOI10.1210/clinem/dgac043 (opens in a new tab)PepBankPUB-35134184
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In people with obesity and diabetes, exenatide decreased left putamen food-cue activation versus placebo after 10 days.

    In plain wordsIn people with obesity and diabetes, exenatide decreased left putamen food-cue activation versus placebo after 10 days.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLeft putamen food-cue activation
    Study

    n: not reported in source

    Comparator
    Double placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 µg twice daily · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After 10 days, dapagliflozin increased, whereas exenatide decreased CNS activation in the left putamen.
    2 context sentences
    Summary · context
    This was a 16-week, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Obese participants with type 2 diabetes (n = 64, age 63.5 ± 0.9 years, BMI 31.7 ± 0.6 kg/m2) were randomized (1:1:1:1) to dapagliflozin 10 mg with exenatide-matched placebo, exenatide twice daily 10 µg with dapagliflozin-matched placebo, dapagliflozin and exenatide, or double placebo.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism

    In people with obesity and diabetes, dapagliflozin-exenatide did not affect food-picture brain responses versus placebo after 10 days.

    In plain wordsIn people with obesity and diabetes, dapagliflozin-exenatide did not affect food-picture brain responses versus placebo after 10 days.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFood-picture brain responses
    Study

    n: not reported in source

    Comparator
    Double placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Combination therapy had no effect on responses to food pictures.
    3 context sentences
    Summary · context
    After 10 days, dapagliflozin increased, whereas exenatide decreased CNS activation in the left putamen.
    Summary · context
    This was a 16-week, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Obese participants with type 2 diabetes (n = 64, age 63.5 ± 0.9 years, BMI 31.7 ± 0.6 kg/m2) were randomized (1:1:1:1) to dapagliflozin 10 mg with exenatide-matched placebo, exenatide twice daily 10 µg with dapagliflozin-matched placebo, dapagliflozin and exenatide, or double placebo.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism

    In people with obesity and diabetes, dapagliflozin-exenatide reduced right amygdala food-cue activation versus placebo after 16 weeks.

    In plain wordsIn people with obesity and diabetes, dapagliflozin-exenatide reduced right amygdala food-cue activation versus placebo after 16 weeks.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseRight amygdala food-cue activation
    Study

    n: not reported in source

    Comparator
    Double placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    After 16 weeks, no changes in CNS activation were observed with dapagliflozin, but CNS activation was reduced with dapagliflozin-exenatide in right amygdala.
    2 context sentences
    Summary · context
    This was a 16-week, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Obese participants with type 2 diabetes (n = 64, age 63.5 ± 0.9 years, BMI 31.7 ± 0.6 kg/m2) were randomized (1:1:1:1) to dapagliflozin 10 mg with exenatide-matched placebo, exenatide twice daily 10 µg with dapagliflozin-matched placebo, dapagliflozin and exenatide, or double placebo.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03361098

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Amsterdam UMC, location VUmcn = 6518 Sept 2017 to 25 Mar 2020

Type 2 Diabetes Mellitus · Obesity

Trial pageClinicalTrials.govUpdated 11 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.